Bristol-Myers Squibb, Merck & Co Drugs Show Promise In Early Trials For Hodgkin’s Lymphoma

December 8, 2014 10:06 AM

15 0

Bristol-Myers’ Opdivo and Merck’s Keytruda showed promise in two separate studies for the treatment of Hodgkin’s lymphoma, adding to the list of potential indications the two cancer immunotherapy drugs can be used to treat

Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.’s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin’s lymphoma in two separate studies, researchers announced Saturday.

Read more

To category page